Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
The Latest on: On-demand vaccines
via Google News
The Latest on: On-demand vaccines
- Racing to control monkeypox, state orders clinics to provide only one vaccine dose per personon August 9, 2022 at 7:42 am
The goal is to give some protection to as many people as possible until more vaccine becomes available, in the hope of reining in a fast-spreading virus that has caught the nation by surprise. The ...
- Major test of first possible Lyme vaccine in 20 years beginson August 9, 2022 at 7:20 am
Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years — in hopes of better fighting the ...
- Covid Vaccine Maker Novavax Tumbles After Cutting Annual Sales Forecast 50%on August 9, 2022 at 6:47 am
Novavax Inc. shares had their biggest loss in more than three years as the drugmaker slashed its 2022 revenue forecast late Monday on disappointing demand for its Covid-19 vaccine that trailed ...
- Pfizer working on Lyme disease vaccineon August 9, 2022 at 6:40 am
Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.
- Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire?on August 9, 2022 at 6:21 am
A hasty decision to try an unproven and risky strategy to stretch the existing monkeypox vaccine supply may interfere with developing a national plan to quell this outbreak.
- BioNTech expects Omicron-adapted vaccine deliveries as soon as Octoberon August 9, 2022 at 5:50 am
BioNTech is expected to be making deliveries of two Omicron-adapted vaccines as soon as October, which will help generate demand for the fourth quarter.
- Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecaston August 9, 2022 at 4:36 am
U.S. vaccine maker Novavax slumped nearly 31% on Tuesday as falling demand for its COVID-19 shot from low- and middle-income nations led the company to cut its annual revenue expectation by half.
- Fish Vaccine Market Growth Challenges 2022 Future Trends, Business Opportunity, Development Plans, Demand Scope and Industry Size Forecast to 2028on August 9, 2022 at 2:56 am
A quantitative analysis is combined with a fresh perspective on the target industry in the Fish Vaccine Market study.
- ‘It's Been Very Significant': High Demand for Monkeypox Vaccine in Conn.on August 8, 2022 at 7:15 pm
Demand has been intense for the monkeypox vaccine here in Connecticut. It’s been a week since the state launched a limited vaccination effort geared toward those most at risk of contracting the virus.
- Novavax sinks after halving sales forecast on low vaccine demand, supply gluton August 8, 2022 at 2:54 pm
Novavax Inc on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut and soft demand, ...
via Bing News